News about Insight Medbotics, our technology and our team.

Dr. Alexander Kutikov, Chair of the Department of Urology at Fox Chase Cancer Center, was among the first urologists to meet Glenn™, our next-generation, MRI-compatible robotics platform designed for precision in prostate cancer care. The discussion focused on how Glenn’s real MRI guidance changes the prostate care paradigm, and that idea’s resonance with practicing urologists.

What can you expect from Insight Medbotics at the AUA Innovation Nexus showcase? CEO Fazila Seker outlines the challenges in bringing real MRI guidance to prostate cancer care and what we’ve learned from urologists about closing the precision gap.

Insight Medbotics is among the 43 global innovators presenting at the @American Urology Association’s 2026 Innovation Nexus Showcase on May 14 in Washington, DC. As leading organizational advocate for best practice in urology, AUA’s one-day event offers a first look at emerging technologies shaping innovation in urologic care to investors and its 24,000 worldwide members.

What urologists working in a range of clinical settings, such as Hoag’s Dr. Jeffrey C. Bassett, are teaching us about the need for greater precision in prostate cancer care.

Insight Medbotics announced November 13, 2025, that independent urologists have given its next-generation robotics system, Glenn™, strong and positive feedback on its early design and usability. The feedback was shared through a series of private, invitation-only meetings during the Large Urology Group Practice Association’s (LUGPA) Annual Meeting in Chicago.

Insight Medbotics CEO and Board of Directors member Fazila Seker spoke at TechTO's Health Toronto event on September 10, 2025. Her talk, “The Craft of Building Traction for your MedTech Startup: Untold Stories from the Road Less Traveled,” is available to watch on YouTube.

‍Insight Medbotics is an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics. IGAR, the company’s flagship MRI-compatible robot, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot with an MRI, Insight Medbotics is now advancing the technology to improve the standard of precision in prostate cancer care.

Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to welcome Dr. Preston Sprenkle, an Associate Professor of Urology at Yale University, to the company’s clinical advisory board.

System leveraging 510k-cleared IGAR technology attracts growing interest from urologists across U.S. hospitals and private practices

Insight Medbotics CEO and Board of Directors member Fazila Seker was among the healthcare leaders speaking at TechTO’s Health Toronto event on September 10, 2025. Her talk, “The Craft of Building Traction for your MedTech Startup: Untold Stories from the Road Less Traveled,” helped builders in the audience to understand their target customers, how industry alliances work, and gain the insight needed to create traction in a challenging technology market.